Medtronic Receives FDA Approval And Launches Two New Cardiac Resynchronization Therapy Quadripolar Leads

Medtronic, Inc. recently announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of two additional Attain Performa left ventricular (LV) quadripolar leads, which can be paired with the Medtronic Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D) to treat patients with heart failure.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news